How to buy Biophytis SA stock (Biophytis SA)

Biophytis SA is a biotechnology business based in the US. Biophytis SA shares (BPTS) are listed on the NASDAQ and all prices are listed in US Dollars. Biophytis SA employs 22 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Biophytis stock

Buy Biophytis SA stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Biophytis SA stock price (NASDAQ: BPTS)

Use our graph to track the performance of BPTS stocks over time.

Biophytis SA shares at a glance

• Key figures

Information last updated 2024-08-25.

52-week range	$5.44 - $34.24
50-day moving average more info button	$14.20
200-day moving average more info button	$30.20
Wall St. target price	$6,000.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-128.39

Is it a good time to buy Biophytis SA stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biophytis SA financials

Gross profit TTM	$0
Return on assets TTM	-52.78%
Return on equity TTM	-1244.4%
Profit margin	0%
Book value	$0.00
Market Capitalization more info button	$2.6 million

TTM: trailing 12 months

Biophytis SA share dividends

We're not expecting Biophytis SA to pay a dividend over the next 12 months.

You may also wish to consider:

• CVS Health (CVS.US) (5.87% forward annual dividend yield)
• UnitedHealth Group Incorporated (UNH.US) (1.68% forward annual dividend yield)
• McKesson Corporation (MCK.US) (0.5% forward annual dividend yield)

Have Biophytis SA's shares ever split?

Biophytis SA's shares were split on a 1:40 basis on 22 April 2024 . So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Biophytis SA shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Biophytis SA shares which in turn could have impacted Biophytis SA's share price.

Biophytis SA share price volatility

Over the last 12 months, Biophytis SA's shares have ranged in value from as little as $5.44 up to $34.24. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biophytis SA's is 1.05. This would suggest that Biophytis SA's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

To put Biophytis SA's beta into context you can compare it against those of similar companies.

• CVS Health (CVS.US): 0.543
• UnitedHealth Group Incorporated (UNH.US): 0.591
• McKesson Corporation (MCK.US): 0.436

Biophytis SA overview

Biophytis S. A. , a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD.

Frequently asked questions

null
What percentage of Biophytis SA is owned by institutions?
Currently 0.045% of Biophytis SA shares are held by institutions. How many people work for Biophytis SA?
Latest data suggests 22 work at Biophytis SA. When does the fiscal year end for Biophytis SA?
Biophytis SA's fiscal year ends in December. Where is Biophytis SA based?
Biophytis SA's address is: Sorbonne University, Paris, France, 75005 What is Biophytis SA's ISIN number?
Biophytis SA's international securities identification number is: US09076G1040